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THE EARLIEST and still the most con-
vincing evidence fortumour-specific trans-
plantation-type antigens (TSTAs) comes
from the rejection of syngeneic grafts by
suitably immunized recipients. Additional
support has come from the demonstration
of a cell-mediated immune response to
TSTAs, e.g. the transfer of resistance by
lymphoid cells and in vitro cytotoxicity
tests. Serological data from TSTAs in the
case of spontaneous or chemically in-
duced tumours have in general been less
conclusive.
In this note we report experiments
which demonstrate by serology the pre-
sence of a tumour-specific cross-reacting
antigen in the membrane of murine
(DBA/2) lymphomas which, however,
does not act as a target for graft rejection.
The identification byserology ofa tumour-
specific membrane antigen (TSMA) does
not, therefore, imply that the material
measured or isolated is a TSTA, and a
paper from this laboratory (Wolf et al.,
1976), which claimed to have measured
by radioimmunoassay the presence of a
TSTA in the serum of tumour-bearing
mice, must now be corrected. The material
studiedwas aTSMA but not aTSTA ofthe
tumour investigated.
In this report the DBA/2 lymphomas
studied were SL/2, which arose spon-
taneously (seeWolfetal., 1976), L5178Y/E,
a long-passaged methylcholanthrene-in-
duced tumour and L5178Y/ES, its highly
metastatic variant (see Parr, 1972; Davey
et al., 1976). The immunogenicity and
cross-protection of L5178Y/E and
L5178Y/ES were determined by injecting
i.p. 107 lymphoma cells previously irradi-
ated with 5000 rad of X-rays and 7 days
later challenging i.p. with live cells. An
i.p. inoculum of 10 cells from either
tumour into unimmunized mice produces
100% mortality. The Table shows that the
metastatic variant is much less immuno-
genic than the parent lymphoma, and
there is no cross-reactivity between them.
The SL/2 lymphoma had previously been
tested in a similar way (Wolf et al., 1975)
and was of intermediate immunogenicity
and there was no cross-protection with
L5178Y/E.
TABLE.-Immunogenicity and cro88-pro-
tection of the L5178/E, L5178Y/ES and
SL2 lymphomas
Immunization i.p. with
107 107
irradiated irradiated
Challenge L5178Y/E L5178Y/ES
i.p. cells cells
103 L5178Y/E 10/10* 0/10
104 10/10 0/10
105 4/9 0/10
103 L5178Y/ES 0/10 9/10
104 0/10 3/9
105 0/10 0/10
103 SL/2 1/5 0/5
104 0/5 0/5
105 0/5 0/5
107
irradiated
SL/2
cells
1/9
0/10
0/10
0/10
0/10
0/10
5/5
4/5
1/5
* Proportion long-term survivors (tumour-free 56
days after challenge).MEMBRANE ANTIGEN OF MURINE LYMPHOMA
An antiserum to the SL/2 lymphoma
was raised using the general method
described by Motta (1970) in allogeneic
mice with lymphoma cells that had been
pre-treated with an anti-DBA/2 serum
(raised in C57/BL mice with DBA/2 spleen
cells) and described in detail by Wolf et al.
(1976). Complement- (weanling-rabbit-)
(lependent cytotoxic activity of the anti-
serum for the lymphoma cells was deter-
mined as described by Davey et al. (1976)
and is expressed as the percentage of cells
unable to exclude trypan blue after ex-
posure to antibody and complement. The
antiserum was initially cytotoxic for both
normal and malignant DBA/2 tissues, but
successive absorptions on DBA/2 spleen
cells depleted its cytotoxicity for normal
DBA/2 cells without comparable effect on
its cytotoxicity for the 3 DBA/2 lymph-
omas. After 3 absorptions on packed
DBA/2 spleen cells at a ratio of 2:1 by
0
U4
volume for 1-2 h at 4°C, the antiserum
was still highly cytotoxic in the presence
of complement for SL/2, L5178Y/E and
L5178Y/ES, but had no cytotoxicity for
normal DBA/2 spleen cells, lymph-node
cells or thymocytes, nor for 2 non-DBA/2
lymphomas, TLX-9 (syngeneic in C57BL
mice) and TLC-5 (syngeneic in CBA mice)
(see Figure).
These data are consistent with the view
that the antiserum recognizes a tumour-
specific membrane component which is
common to the 3 DBA/2 lymphomas and,
therefore, not a TSTA, as there is no
cross-protection between these tumours.
This observation resembles those of other
workers (Rogers et al., 1978; Lennox &
Sikora, 1977) who have shown that sero-
logically detected highly specific tumour
antigenic determinants are not rejection
antigens. Wolf et al. (1976) had used
absorbed antiserum prepared in the same
SL2
I I _
1: 10 1: 25 1:50 1: 100 1:250 1:500 1: 1000
anitiserum dilution (expressed on a logarithmic scale)
FIG. Cytotoxic activity ofan anti-DBA/2 lymphoma antiserum. Normal DBA/2 cells (spleen, lymph
node and thymus) and allogeneic lymphomas (TLX9 and TLC5) all gave figures of <30% at an
antiserum dilution of 1:10.
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way to isolate and partially to purify a
membrane component from SL/2 lymph-
oma cells, and then used the material so
isolated in a radioimmunoassay for meas-
uring its concentration in the serum of
mice with progressively growing SL/2
tumours. The claim made that this pro-
cedure constituted a measure of circu-
lating TSTA derived from the SL/2
tumour must be withdrawn in the light of
the above data, which show that this anti-
serum combines with a cross-reacting
TSMA which does not elicit graft rejection.
This investigation has been supported by a pro-
gramme grant from the Medical Research Council.
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